Showing results (121-130 of 176) with videos related to
Sort By:
Pageof 18
Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective studyJiang-Tao Cheng, Yi-Hui Yao, Yu-Er Gao, et al.Lung Cancer (Amsterdam, Netherlands)|December 6, 2022
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survivalChan-Yuan Zhang, Hao Sun, Jun-Wei Su, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 2, 2018
EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor OsimertinibQi Zhang, Xu-Chao Zhang, Jin-Ji Yang, et al.The Lancet. Oncology|July 11, 2015
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialJean-Charles Soria, Yi-Long Wu, Kazuhiko Nakagawa, et al.Cancer Immunology, Immunotherapy : CII|October 20, 2021
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II studyJin-Ji Yang, Cheng Huang, Yun Fan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2014
Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylationJin-Ji Yang, Xu-Chao Zhang, Jian Su, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2017
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade ImmunotherapySi-Pei Wu, Ri-Qiang Liao, Hai-Yan Tu, et al.Journal of Thoracic Disease|October 23, 2023
Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancerShi-Ling Zhang, Chan-Yuan Zhang, Yu-Qing Chen, et al.Oncotarget|August 18, 2016
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsNa-Na Lou, Xu-Chao Zhang, Hua-Jun Chen, et al.Lung Cancer (Amsterdam, Netherlands)|August 27, 2024
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimenKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.Pageof 18